Dr. Reddy’s Laboratories (DRL) has launched hydroxychloroquine sulfate tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil tablets, in the U.S. market.
Used in the treatment of malaria, lupus erythematosus and rheumatoid arthritis, the product is being launched by the company along with subsidiaries with approval of the U.S. Food and Drug Administration (USFDA), a Dr.Reddy's statement on Wednesday said.
Plaquenil is a trademark of Concordia International Corp. Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
